Security
Rocket Pharmaceuticals, Inc. Common Stock · RCKT
RCKTNASDAQCommon stockCurrentCIK 1281895Updated Oct 7, 2026
Name history
INOTEK PHARMACEUTICALS CORP · through Dec 22, 2017
RCKT price & chart
Loading TradingView…
NASDAQ:RCKT on TradingView ↗About the company
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated commercial-stage biotechnology company developing genetic medicines for rare and life-threatening diseases, with a strategic focus on inherited cardiovascular disorders and additional programs in hematology and immunology. Rocket's cardiovascular portfolio includes three clinical-stage gene therapy programs targeting hypertrophic, arrhythmogenic, and dilated cardiomyopathies, together representing one of the broadest pipelines focused on inherited heart disease. The Company’s integrated platform combines proprietary adeno-associated virus (AAV) manufacturing capabilities and extensive clinical experience in cardiac gene therapy.
In the news
DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025 News provided by Berger Montague Aug 08, 2025, 14:16 ET Share this article Share to X Share this article Share to X PHILADELPHIA , Aug. 8, 2025 /PRNewswire/ -- Berg ↗
Recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 2.03, 3.02, 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
144 filing
25-NSE - filed by Nasdaq Stock Market LLC regarding ROCKET PHARMACEUTICALS, INC.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 330,449,000Source | 527,700,000Source | 566,341,000Source | 551,807,000Source |
| Property, Plant and Equipment, NetUSD | 28,170,000Source | 36,786,000Source | 39,172,000Source | 29,009,000Source |
| GoodwillUSD | 39,154,000Source | 39,154,000Source | 39,154,000Source | 39,154,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 25,150,000Source | 25,150,000Source | 25,150,000Source | 25,724,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 77,558,000Source | 163,635,000Source | 55,904,000Source | 140,517,000Source |
| Assets, CurrentUSD | 192,734,000Source | 378,183,000Source | 378,222,000Source | 364,060,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,805,000Source | 5,847,000Source | 5,047,000Source | 7,666,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,210,000Source | 4,173,000Source | 3,901,000Source | 1,972,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 53,228,000Source | 64,466,000Source | 73,767,000Source | 62,121,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,083,000Source | 1,065,000Source | 903,000Source | 791,000Source |
| Additional Paid in CapitalUSD | 1,717,408,000Source | 1,680,219,000Source | 1,450,722,000Source | 1,203,074,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,441,239,000Source | -1,218,116,000Source | -959,370,000Source | -713,775,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -31,000Source | 66,000Source | 319,000Source | -357,000Source |
| Stockholders' Equity Attributable to ParentUSD | 277,221,000Source | 463,234,000Source | 492,574,000Source | 489,686,000Source |
| Liabilities and EquityUSD | 330,449,000Source | 527,700,000Source | 566,341,000Source | 551,807,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 30,206,000Source | 40,684,000Source | 48,505,000Source | 39,169,000Source |
| Operating Lease, Liability, CurrentUSD | 1,003,000Source | 1,001,000Source | 925,000Source | 773,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,600,000Source | 3,258,000Source | 2,973,000Source | 1,088,000Source |
| Other Liabilities, NoncurrentUSD | 1,060,000Source | 1,141,000Source | 2,936,000Source | 2,595,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 188,900,000Source | 372,300,000Source | 407,500,000Source | — |
| Deferred Tax Liabilities, NetUSD | 1,061,000Source | 1,061,000Source | 1,061,000Source | 1,061,000Source |
| Short-term InvestmentsUSD | 111,371,000Source | 208,701,000Source | 317,271,000Source | 215,877,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 8,900,000Source | 7,200,000Source | 4,900,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 37,059,000Source | 43,920,000Source | 39,406,000Source | 31,009,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -190,014,000Source | -209,724,000Source | -194,916,000Source | -178,142,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 103,767,000Source | 131,706,000Source | -98,066,000Source | -69,326,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 440,000Source | 5,862,000Source | 16,436,000Source | 8,358,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 148,000Source | 185,739,000Source | 208,401,000Source | 155,288,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 78,898,000Source | 164,997,000Source | 57,276,000Source | 141,857,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 0Source | 0Source |
| Income Taxes Paid, NetUSD | 0Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 37,059,000Source | 43,920,000Source | 39,406,000Source | 31,009,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 188,900,000Source | 372,300,000Source | 407,500,000Source | — |
| General and Administrative ExpenseUSD | 86,501,000Source | 101,961,000Source | 73,317,000Source | 58,773,000Source |
| GoodwillUSD | 39,154,000Source | 39,154,000Source | 39,154,000Source | 39,154,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | 0Source | 574,000Source | — |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 0Source | 0Source | — |
| Income Tax Expense (Benefit)USD | 0Source | — | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | -223,123,000Source | -258,746,000Source | -245,595,000Source | -221,863,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -223,123,000Source | -258,746,000Source | -245,595,000Source | -221,863,000Source |
| Nonoperating Income (Expense)USD | — | — | — | 2,480,000Source |
| Operating ExpensesUSD | 231,747,000Source | 273,205,000Source | 259,659,000Source | 224,343,000Source |
| Operating Lease, Impairment LossUSD | 262,000Source | — | — | — |
| Payments to Acquire InvestmentsUSD | 276,553,000Source | 245,886,000Source | 390,920,000Source | 376,327,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 46,566,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 3,211,000Source | 2,231,000Source | 631,000Source |
| Realized Investment Gains (Losses)USD | 0Source | 0Source | 0Source | 0Source |
| Unrealized Gain (Loss) on InvestmentsUSD | -97,000Source | -253,000Source | 676,000Source | 196,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 0Source | 0Source | 0Source |
| Operating Income (Loss)USD | -231,747,000Source | -273,205,000Source | -259,659,000Source | -224,343,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -223,123,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | — | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | -223,123,000Source | -258,746,000Source | -245,595,000Source | -221,863,000Source |
| Earnings Per Share, BasicUSD per share | -2.01Source | -2.73Source | -2.92Source | -3.26Source |
| Earnings Per Share, DilutedUSD per share | -2.01Source | -2.73Source | -2.92Source | -3.26Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 111,123,770Source | 94,807,773Source | 84,009,004Source | 68,148,925Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 111,123,770Source | 94,807,773Source | 84,009,004Source | 68,148,925Source |
| Additional Financial Items | ||||
| Direct Costs of Leased and Rented Property or EquipmentUSD | 1,100,000Source | 1,500,000Source | 2,300,000Source | 1,200,000Source |
| General and Administrative ExpenseUSD | 86,501,000Source | 101,961,000Source | 73,317,000Source | 58,773,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Interest and Other IncomeUSD | 3,218,000Source | 8,267,000Source | 5,288,000Source | 3,889,000Source |
| Interest ExpenseUSD | 1,891,000Source | 1,886,000Source | 1,875,000Source | 1,862,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -223,123,000Source | -258,746,000Source | -245,595,000Source | -221,863,000Source |
| Nonoperating Income (Expense)USD | — | — | — | 2,480,000Source |
| Operating ExpensesUSD | 231,747,000Source | 273,205,000Source | 259,659,000Source | 224,343,000Source |
| Realized Investment Gains (Losses)USD | 0Source | 0Source | 0Source | 0Source |
| Research and Development ExpenseUSD | 142,015,000Source | 171,244,000Source | 186,342,000Source | 165,570,000Source |
Offerings
Registration 333-293925
Filing attachments
ef20083350_ex99-1.htm · 8-K · 2026-10-06
Exhibit 99.1 Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital CRANBURY, N.J. - October 6, 2026 - Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 mill…
Read attachment ↗ef20083350_ex99-2.htm · 8-K · 2026-10-06
Exhibit 99.2 RP-A501 Danon Disease Program Update © 2026 Rocket Pharmaceuticals Rocket Pharmaceuticals October 6, 2026 DISCLAIMER 2 © 2026 Rocket Pharmaceuticals This presentation contains forward-looking statements concerning Rocket’s future expectations, plans and prospects that involverisks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause actual results to differ materially from those expressed or implied by such forward-looking stat…
Read attachment ↗ef20082010_ex99-1.htm · 8-K · 2026-09-15
EX-99.1 2 ef20082010_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol FDA review of initial safety data supports continued enrollment and dosing under modified protocol FDA confirms established 12-month co-primary endpoints intended to support potential accelerated …
Read attachment ↗ef20079821_ex99-1.htm · 8-K · 2026-08-10
EX-99.1 2 ef20079821_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic microangiopathy, capillary leak syndrome, or other significant safety concerns observed Rocket is actively engaging with the FDA to align on the path to rapidly completin…
Read attachment ↗ef20079241_ex99-1.htm · 8-K · 2026-08-03
EX-99.1 2 ef20079241_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observed Rocket is actively engaging with the FDA to align on the path to pivotal trial completion; regulatory pathway update expected in the second half of 202…
Read attachment ↗ef20077364_ex107.htm · S-8 · 2026-07-14
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) ROCKET PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Maximum Aggregate Fee Rate Amount of Registration Fee …
Read attachment ↗